Molybdenum Disulfide Nanocomposites for Cancer Diagnosis and Therapeutics: Biosensors, Bioimaging, and Phototherapy

Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown

Published: April 27, 2025

Abstract Molybdenum disulfide (MoS₂) nanomaterials have attracted significant interest in cancer diagnosis and therapy due to their unique physicochemical properties. Due its extensive surface area adaptable structure, MoS₂ may engage with pharmaceuticals biomolecules via covalent non‐covalent interactions. This versatility enhances the sensitivity of identifying specific biomarkers, colloidal stability, tumor‐targeting capabilities. In near‐infrared (NIR) spectrum, exhibits strong optical absorption efficient photothermal conversion, making it suitable for NIR‐driven phototherapy regulated medication release. Functionalized nanocomposites react differently tumor microenvironment, which improves treatment effectiveness by increasing drug accumulation at sites decreasing off‐target effects on healthy tissues. Recent developments MoS₂‐based detection are reviewed this study, particular attention paid uses therapy, photodynamic biosensing, bioimaging. Additionally, looks difficulties potential applications cancer.

Language: Английский

Comparison of nose-to-brain and systemic delivery of STING agonist-loaded liposomes for glioblastoma treatment

Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 107000 - 107000

Published: May 1, 2025

Language: Английский

Conjugated Polymer-Photosensitizers for Cancer Photodynamic Therapy and Their Multimodal Treatment Strategies

Polymers, Journal Year: 2025, Volume and Issue: 17(9), P. 1258 - 1258

Published: May 5, 2025

Conjugated polymers (CPs) have emerged as promising candidates for photodynamic therapy (PDT) in cancer treatment due to their high fluorescence quantum yield, excellent photostability, and remarkable reactive oxygen species (ROS) generation capability. This review systematically summarizes molecular design strategies augment CP photosensitivity efficiency, including: (1) constructing donor–acceptor (D-A) alternating structures, (2) incorporating aggregation-induced emission (AIE) moieties, (3) employing heavy-atom effects, (4) designing hyperbranched architectures. In addition, considering the limitations of monotherapy like tumor heterogeneity, we will further discuss synergistic CP-mediated PDT combination with other therapeutic modalities, including photothermal (PTT)-PDT, immunotherapy-PDT, chemotherapy-PDT, Chemiluminescence (CL)-PDT, diagnostic technology-PDT, chemodynamic (CDT)-PDT. These multimodal approaches leverage complementary mechanisms achieve enhanced eradication efficacy.

Language: Английский